Compare Aurora Cannabis Inc (ACB) vs DexCom, Inc. (DXCM) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Aurora Cannabis Inc vs DexCom, Inc. — how do they compare? Aurora Cannabis Inc trades at $3.82 (market cap $223.59M), while DexCom, Inc. trades at $90.64 (market cap $33.79B). The key difference: DexCom, Inc. is far larger — about 151.1× Aurora Cannabis Inc's market cap, and DexCom, Inc. is trading nearer its 52-week high, Aurora Cannabis Inc nearer its low. Which is the better fit depends on your goals.
| ACB | DXCM | |
|---|---|---|
Market Cap | $223.59M | $33.79B |
Sector | Health | Health |
52-Week High | $6.23 | $89.53 |
52-Week Low | $2.58 | $54.84 |
Enterprise Value | $168.09M | $33.24B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aurora Cannabis (ACB) trades at $3.82, up 32.18% amid Curaleaf's hostile takeover bid offering a 45% premium. The stock shows mixed technical signals with neutral RSI but bearish moving averages. Fundamentally, ACB achieved profitability in 2025 with $1.59M net income after years of losses, though 2026 projections show renewed negative margins. Revenue grew 27% year-over-year to $343M, but the company faces significant execution risks in a competitive cannabis market.
The takeover bid creates near-term upside potential to $4 per share, but standalone prospects remain challenged by negative profitability projections and competitive pressures. Investors face a binary outcome: accept the premium offer or risk ACB's volatile standalone execution amid declining 2026 revenue and negative margins.
DXCM trades at $91.00, up 3.82% today and near its 52-week high, with bullish technical signals from moving averages and strong fundamentals. Recent Q2 2026 earnings beat expectations with EPS of $0.70 versus $0.61 expected, driven by 13% revenue growth and margin expansion. The company raised full-year 2026 guidance, reflecting robust demand for continuous glucose monitors.
The outlook is positive due to sustained revenue growth, profitability improvements, and analyst consensus favoring buys. Risks include competitive pressures and potential regulatory scrutiny, but institutional ownership trends and earnings momentum support a constructive view for investors seeking exposure to medical technology.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Aurora Cannabis Inc
Aurora Cannabis, based in Edmonton, Canada, grows and distributes both medical and recreational cannabis under several brands, including Drift, San Rafael '71, Daily Special, Whistler, Being, and Greybeard. While its main market is Canada, the company has also expanded globally through medical cannabis export agreements.
Read more on ACB →About DexCom, Inc.
Dexcom designs and commercializes continuous glucose monitoring systems for diabetics. CGM systems serve as an alternative to the traditional blood glucose meter process, and the company is evolving its CGM systems to include the disposable sensor and the durable receiver.
Read more on DXCM →
